Romanini B M, Sandri M G, Tosi M, Mezzetti M, Mazzetti A
Int J Clin Pharmacol Res. 1986;6(2):123-7.
A double-blind clinical trial has been carried out with 40 patients hospitalized for thoracic pathology requiring surgery (cancer of the lungs, hamartoma, pleural mesothelioma, bullous dystrophy or emphysema of the lung). The purpose was to determine the effectiveness of the drug in preventing and in treating postoperative bronchopulmonary complications. The results showed that the patients treated with 1g of ambroxol for three days before surgery, on the day of the operation and for five days afterwards had a more rapid turnover of intra-alveolar surface tension and better re-expansion of the pulmonary parenchyma after surgery. They also had better mucociliary clearance of the respiratory tract. These improvements are indispensable for limiting bronchopulmonary complications after chest surgery.
对40名因胸部病变需要手术（肺癌、错构瘤、胸膜间皮瘤、肺大疱性营养不良或肺气肿）而住院的患者进行了一项双盲临床试验。目的是确定该药物在预防和治疗术后支气管肺并发症方面的有效性。结果表明，术前三天、手术当天及术后五天使用1克氨溴索治疗的患者，肺泡表面张力周转更快，术后肺实质再扩张更好。他们的呼吸道黏液纤毛清除功能也更好。这些改善对于限制胸部手术后的支气管肺并发症是必不可少的。
